Time is Brain

Time is Brain operates in the neurological monitoring and digital-medtech segment, with a specific emphasis on stroke pathways and bedside brain-viability assessment. Its principal differentiation is BraiN20®, which the company positions as a non-invasive system capable of continuously monitoring brain viability in real time rather than relying only on intermittent examinations or conventional diagnostic snapshots. The product is aimed at medical professionals who need rapid information during time-sensitive neurological care. Its origins as a spin-off from Hospital Germans Trias i Pujol and its involvement in clinical research provide an academic and hospital-connected profile, while CE marking under the EU Medical Device Regulation supports use within the European regulatory framework. This limits confidence in assessing market share, pricing, clinical adoption, and differentiation against established neurodiagnostic and EEG-monitoring providers.

Time is Brain’s trajectory combines an academic clinical origin, product development, regulatory progress, and a recently disclosed financing event. Founded in 2020 as a spin-off from Hospital Germans Trias i Pujol, the company has focused on translating neurological and stroke-care expertise into BraiN20®, a non-invasive bedside monitoring device. The product’s claimed ability to continuously assess brain viability represents the central technical inflection point, shifting the offering from research-oriented monitoring toward a tool intended for time-critical clinical decisions. On Jul 10, 2026, the company announced a €3 million Pre-Series A, approximately $3.27 million, providing capital for continued product development, clinical work, and market execution. The presence of a careers page suggests continued organizational activity, but there is no disclosed headcount or quantified employee-growth trend.